Fig. 2From: A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorderStandard Protocol Items: Recommendations for Interventional Trials (SPIRIT)Back to article page